These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30210856)

  • 1. Rituximab Treatment in
    Koul R; Al-Futaisi A; Abdelrahim R; Mani R; Abdwani R; Al-Asmi A
    Sultan Qaboos Univ Med J; 2018 May; 18(2):e223-e227. PubMed ID: 30210856
    [No Abstract]   [Full Text] [Related]  

  • 2. Selective response to rituximab in a young child with MuSK-associated myasthenia gravis.
    Govindarajan R; Iyadurai SJ; Connolly A; Zaidman C
    Neuromuscul Disord; 2015 Aug; 25(8):651-2. PubMed ID: 25998611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab.
    Jonsson DI; Pirskanen R; Piehl F
    Neuromuscul Disord; 2017 Jun; 27(6):565-568. PubMed ID: 28433474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab treatment of myasthenia gravis: A systematic review.
    Tandan R; Hehir MK; Waheed W; Howard DB
    Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memory B cell resurgence requires repeated rituximab in myasthenia gravis.
    Muto K; Matsui N; Unai Y; Sakai W; Haji S; Udaka K; Miki H; Furukawa T; Abe M; Kaji R
    Neuromuscul Disord; 2017 Oct; 27(10):918-922. PubMed ID: 28694074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.
    Iorio R; Damato V; Alboini PE; Evoli A
    J Neurol; 2015 May; 262(5):1115-9. PubMed ID: 25308632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
    Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
    J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 10-year-outcomes after rituximab for myasthenia gravis: Efficacy, safety, costs of inhospital care, and impact on childbearing potential.
    Stieglbauer K; Pichler R; Topakian R
    J Neurol Sci; 2017 Apr; 375():241-244. PubMed ID: 28320139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature.
    Koul R; Al Futaisi A; Abdwani R
    Pediatr Neurol; 2012 Sep; 47(3):209-12. PubMed ID: 22883288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use and monitoring of low dose rituximab in myasthenia gravis.
    Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in late-onset myasthenia gravis is safe and effective.
    Sahai SK; Maghzi AH; Lewis RA
    Muscle Nerve; 2020 Sep; 62(3):377-380. PubMed ID: 32239711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Refractory myasthenia gravis with good response to rituximab. Report of one case].
    Suárez H F; Urrutia E D
    Rev Med Chil; 2020 Jul; 148(7):1031-1033. PubMed ID: 33399689
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab.
    Chan F; Swayne A; Gillis D; Walsh M; Henderson RD; McCombe PA; Wong RC; Blum S
    J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):955-956. PubMed ID: 30455407
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India.
    Sachdeva J; Mahesh KV; Shree R; Jain G; Kapila AT; Shashikala TP; Goyal MK; Modi M; Lal V
    Indian J Pharmacol; 2020; 52(1):49-52. PubMed ID: 32201447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
    Li H; Huang Z; Jia D; Xue H; Pan J; Zhang M; Shi K; Shi FD; Zhang C
    J Neuroimmunol; 2021 May; 354():577528. PubMed ID: 33662696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review.
    Nelson RP; Pascuzzi RM; Kessler K; Walsh LE; Faught PP; Ramanuja S; Pescovitz MD; Loehrer PJ
    J Clin Neuromuscul Dis; 2009 Jun; 10(4):170-7. PubMed ID: 19494727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to rituximab in an anti-muscle-specific receptor tyrosine kinase- and anti-acetylcholine recepto-double-positive myasthenia gravis patient concomitant with follicular dendritic cell sarcoma.
    Wang J; Wu X; Deng H; Liu Y; Liu H; Fan X; Liu K; Wu J; Zhang HL
    Neurosciences (Riyadh); 2016 Jan; 21(1):77-8. PubMed ID: 26818174
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
    Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab in the management of refractory myasthenia gravis.
    Zebardast N; Patwa HS; Novella SP; Goldstein JM
    Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.